ClinicalTrials.gg
Active, not recruitingNCT04194554ASCLEPIuSUpdated May 1, 2026

A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer

A Phase 1/2 interventional study of Niraparib and Leuprolide in Prostate Cancer, sponsored by University of Michigan Rogel Cancer Center. Active, not recruiting at 6 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-01.

Sponsored by University of Michigan Rogel Cancer Center · Phase 1/2, Interventional, and Treatment

How we know · 7 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
102
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies testing niraparib in Prostatic Neoplasms — 3 open to participants now, 7 under way, 2 of them phase 3. niraparib · Prostatic Neoplasms.

Enrollment
8th of 19
102 · median 34
Started
2020
with 3 others
Phase 1/2
3 of 19
none open now
Registered
9th of 19
by date

Among the 19 studies testing niraparib in Prostatic Neoplasms, this one is the 8th largest by enrollment, is one of 4 that started in 2020, is one of 3 in phase 1/2, and was the 9th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

3 of the 19 studies testing niraparib in Prostatic Neoplasms are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About niraparib

niraparib: first FDA approval 2017 (ZEJULA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing niraparib in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to establish the maximum tolerable dose of niraparib when combined with prostate stereotactic body radiotherapy (SBRT), abiraterone, leuprolide, and prednisone (the phase 1 portion of the study) and determine 3-year biochemical PSA recurrence free-survival with this treatment approach (the phase 2 portion of the study).

03

Conditions studied

  • Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Pathologic proven adenocarcinoma of the prostate
  2. At least one of the following criteria:

    • cN1 on conventional or PET imaging
    • Grade group 5
    • Grade group 4
    • Grade group 3 and PSA ≥20 ng/mL
    • High probability of Radiographic T3 on MRI AND Grade group ≥2
    • Grade Group 3 AND PSA ≥10 ng/mL AND ≥50% positive biopsy cores
  3. Age ≥ 18
  4. \< 1
  5. Adequate organ and marrow function as defined per protocol.
  6. Use of highly effective (e.g. condoms) for the duration of treatment and a minimum of 120 days thereafter. Men must also agree not to donate sperm for the duration of the study participation, and for at least 120 days thereafter.
  7. International Prostate Symptoms Score (IPSS) ≤ 20
  8. Medically fit for treatment and agreeable to follow-up
  9. Ability to understand and the willingness to sign a written
  10. Tissue available for MiOncoSeq testing to assign DNA repair deficiency status

Exclusion criteria

Exclusion Criteria

  1. Clinical or radiographic evidence of distant disease by CT/bone scan
  2. Clinical or radiographic evidence of high probability of clinical T4 disease
  3. Prostate gland size >80 cc measured by ultrasound or MRI
  4. Prominent median lobe assessed by treating physician
  5. Lack of tissue from to be sent for correlative studies
  6. Any prior treatment for prostate cancer (incudes history of TURP within 5 years of enrollment, chemotherapy, radiation therapy, or anti-androgen therapy)
  7. Prohibited within 30 days prior to administration to study treatment: spironolactone and other drug therapies.
  8. Prohibited 3 months before participant registration and during administration of study treatment: non-steroidal anti-androgens (e.g., bicalutamide, flutamide, nilutamide), steroidal antiandrogens (megestrol acetate, cyproterone acetate), oral ketoconazole, chemotherapy, immunotherapy, estrogens, radiopharmaceuticals.
  9. History of prior pelvic radiation therapy
  10. Concurrent treatment with strong inducers such as phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital
  11. Enrollment concurrently in another investigational drug study within 1 month of registration
  12. History of another active within the previous 3 years except for adequately treated skin cancer or superficial bladder cancer
  13. History of or active Crohn's disease or ulcerative colitis
  14. to or inability to tolerate MRIs
  15. Patients with severe depression
  16. Uncontrolled diabetes or known >10
  17. Any gastrointestinal disorder affecting absorption
  18. Active pituitary or adrenal dysfunction
  19. Patients with significant cardiovascular disease potentially including severe / unstable angina, recent history of myocardial infarction, heart failure, cerebrovascular disease, venous thromboembolic events, clinically significant arrhythmias)
  20. Uncontrolled hypertension with persistently elevated systolic blood pressure >160 mmgHg or diastolic blood pressure >100 mmHg despite anti-hypertensive agents.
  21. Prolonged >450 ms or any changes that interfere with QT interval interpretation
  22. Major surgery within 1 month of registration
  23. History of myelodysplastic syndrome or leukemia
  24. A known to niraparib, abiraterone acetate, leuprolide, and/or prednisone
  25. Active infection or other medical condition that would be a contraindication to prednisone use
  26. Patients with known active hepatitis or chronic liver disease including cirrhosis
  27. Any condition that in the opinion of the investigator would preclude participation in this study
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
102 participants (actual)

Study arms

  • Experimental
    Niraparid Dose Escalation

    Dose Level 1: 100 mg PO daily of Niraparib but held for 5 days (+/- 2 days) prior to RT, during SBRT, and 5 days (+/- 2 days) after last fraction of SBRT Dose Level 2: 200 mg PO daily of Niraparib but held for 5 days (+/- 2 days) prior to RT, during SBRT, and 5 days (+/- 2 days) after last fraction of SBRT Dose Level 3: 200 mg PO daily of Niraparib without breaks during SBRT until completion of 6 cycles.

    Drug: Niraparib · Drug: Leuprolide · Drug: Abiraterone Acetate · Radiation: Stereotactic body radiotherapy (SBRT)

Interventions

  • given PO per dose escalation schedule

  • 22.5 mg q3 month

  • 1000 mg daily

  • RadiationStereotactic body radiotherapy (SBRT)

    5-6 fraction SBRT (total dose: 37.5-40 Gy)

    Also known as: Ultra-hypofractionated radiotherapy

06

What researchers measure

Primary outcomes

  1. Dose-limiting toxicities (Phase 1)

    The proportion of patients at each dose level with dose-limiting toxicity (DLT), defined as any treatment related grade 3-5 adverse event experienced within the first 4 treatment cycles (112 days), assessed per NCI's CTCAE version 5.0.

    Time frame: Up to 112 days after initial dose of niraparib

  2. Proportion of patients experiencing biochemical failure

    Change in PSA level from the beginning of study treatment for up to 3 years later will determine the biochemical failure rate. Biochemical failure will be defined using the Phoenix definition of the PSA nadir + 2 ng/mL.

    Time frame: Up to 3 years after first dose of niraparib

Secondary outcomes

  1. Change in health related quality of life

    Assessed via EPIC-26 questionnaire

    Time frame: From baseline up to 3 years after last dose of niraparib

  2. Proportion of patients with undetectable post-treatment PSA

    Undetectable PSA will be defined as a PSA ≤0.1 ng/mL.

    Time frame: Measured during the end of the 6th cycle of therapy (during week 24 +/- 7 days)

  3. Proportion of patients with distant metastases

    Distant metastases will be defined as any clinical or radiographic evidence of lymph node, bone, or visceral involvement of prostate cancer.

    Time frame: Up to 5 years after first dose of niraparib

  4. Prostate cancer specific survival

    Prostate cancer specific survival will be defined as the duration of time from the start of treatment to death attributable to prostate cancer. Patients who have not died or die of non-prostate cancer related causes will be censored at the last known follow-up or date of death, respectively. Summarized using cumulative incidence or Kaplan-Meier curves as appropriate.

    Time frame: Up to 5 years after first dose of niraparib

  5. Overall survival

    Overall survival (OS) will be defined as the duration of time from the start of treatment to death from any cause. Patients who have not died will be censored at the last known follow-up.Summarized using cumulative incidence or Kaplan-Meier curves as appropriate.

    Time frame: Up to 5 years after first dose of niraparib

07

Study locations

6 sites
08

References and documents

Individual participant data

Plan to share: Yes — Data that may be shared will only include individual participant data that underlie the results reported publicly in ClinicalTrials.gov or published articles, after deidentification (text, tables, figures, appendices).

Supporting information: Study protocol

Time frame: The time frame for data sharing will begin 12 months after the initial publication and continue until 36 months after publication in ClinicalTrials.gov.

Access criteria: Once the final results of the trial have been reported parties interested in accessing the data should contact the trial PI (Dr. Daniel Spratt) to discuss any potential data sharing requests. An analysis plan is required and intended use of the data must be disclosed. Only de-identified data may be shared and all agreements must comply with current policies of both parties to share data.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2020 (actual). Primary completion is estimated for May 2027, 78 months after the start.

Of 114 non-industry phase 1/2 interventional studies under Prostatic Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 85. This study's planned 78 months is above that.

Counting every sponsor, half of 210 studies reached it within 61 months; a quarter within 30 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2019
First posted
Dec 11, 2019
StartActual
Nov 6, 2020
Primary completionEst.
May 2027
CompletionEst.
May 2029
Last update
May 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04194554
Responsible party
Sponsor
First posted
Dec 11, 2019
Start date
Nov 6, 2020
Primary completion
May 2027 (estimated)
Completion
May 2029 (estimated)
Last update
May 1, 2026

Study contacts

Daniel Spratt, M.D.
study chair · Case Western Reserve University - Seidman Comprehensive Cancer Center
William Jackson, M.D.
principal investigator · University of Michigan Rogel Cancer Center

Oversight

FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Niraparib · Leuprolide · Abiraterone Acetate

Start the discussion